3rd Annual Meeting of the Society for Translational Oncology
PERSONALIZING CANCER DIAGNOSIS AND TREATMENT 2012

Hosted by

UNC
LINEBERGER

Saturday–Sunday, October 20-21, 2012
Rizzo Conference Center
Chapel Hill, North Carolina

Go paperless! The meeting brochure and abstract book are available on your iPad or mobile device! Download The Oncologist App today.
# ANNUAL MEETING AGENDA

**Saturday, October 20, 2012**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30a</td>
<td>Registration and Continental Breakfast</td>
</tr>
<tr>
<td>8:00a</td>
<td>Welcome and Introductions</td>
</tr>
<tr>
<td><strong>Hyman B. Muss, MD</strong>, Conference Chair and Treasurer, STO; Professor of Medicine, UNC School of Medicine &amp; Director of the Geriatric Oncology Program, UNC Lineberger</td>
<td><strong>Martin J. Murphy, DMedSc, PhD</strong>, Convener, STO; Executive Editor, <em>The Oncologist</em></td>
</tr>
<tr>
<td>8:10-9:10a</td>
<td>Presentation of the Pinedo Cancer Care Prize and Lecture: Publicly Funded Clinical Trials and the Future of Cancer Care</td>
</tr>
<tr>
<td>9:10-10:30a</td>
<td>New and Novel Imaging</td>
</tr>
<tr>
<td><strong>Joel Tepper, MD</strong>, Hector MacLean Distinguished Professor of Cancer Research, Department of Radiation Oncology, UNC School of Medicine</td>
<td><strong>Terence Z. Wong, MD, PhD</strong>, Associate Professor of Radiology, Duke University Cancer Center</td>
</tr>
<tr>
<td><strong>Otto Zhou, PhD</strong>, David Godschalk Distinguished Professor Department of Physics and Astronomy, and Curriculum in Applied Sciences and Engineering Lineberger Comprehensive Cancer Center</td>
<td><strong>W. Brian Hyslop, MD, PhD</strong>, Associate Professor of Radiology, UNC School of Medicine</td>
</tr>
<tr>
<td><strong>Matthew Ewend, MD</strong>, Kay and Van Weatherspoon Distinguished Professor and Chair, Department of Neurosurgery, UNC School of Medicine</td>
<td><strong>Hong Jin Kim, MD</strong>, Associate Professor, Department of Surgery, Division of Surgical Oncology, UNC School of Medicine</td>
</tr>
<tr>
<td><strong>Hong Jin Kim, MD</strong>, Associate Professor, Department of Surgery, Division of Thoracic Oncology, UNC School of Medicine</td>
<td><strong>Bert O'Neil, MD</strong>, Associate Professor of Medicine, UNC School of Medicine and Medical Director, Clinical Protocol Office, UNC Lineberger</td>
</tr>
<tr>
<td><strong>Lisa A. Carey, MD</strong>, Preyer Distinguished Professor in Breast Cancer Research, Chief, Division of Hematology/Oncology, UNC School of Medicine; Associate Director, Clinical Research, UNC Lineberger Comprehensive Cancer Center</td>
<td><strong>Jen Jen Yeh, MD</strong>, Associate Professor, Departments of Surgery and Pharmacology, Division of Surgical Oncology, UNC School of Medicine</td>
</tr>
<tr>
<td><strong>Stergios J. Moschos, MD</strong>, Clinical Associate Professor of Medicine, UNC School of Medicine</td>
<td><strong>Yueh “Ray” Lee, MD</strong>, Assistant Professor, Radiology, UNC School of Medicine</td>
</tr>
<tr>
<td>10:30-10:50a</td>
<td>Break</td>
</tr>
<tr>
<td><strong>Hong Jin Kim, MD</strong>, Associate Professor, Department of Surgery, Division of Surgical Oncology, UNC School of Medicine</td>
<td><strong>Benjamin Haithcock, MD</strong>, Associate Professor, Department of Surgery, Division of Thoracic Oncology, UNC School of Medicine</td>
</tr>
<tr>
<td><strong>Mathew A. Mauro, MD, FACS, FAHA, FSIR</strong>, Ernest H. Wood Distinguished Professor and Chair, Department of Radiology, UNC School of Medicine</td>
<td><strong>Joel Tepper, MD</strong>, Hector MacLean Distinguished Professor of Cancer Research, Department of Radiation Oncology, UNC School of Medicine</td>
</tr>
<tr>
<td>12:15-1:15p</td>
<td>Lunch</td>
</tr>
<tr>
<td><strong>Lisa A. Carey, MD</strong></td>
<td><strong>Thomas E. Stinchcombe, MD</strong>, Associate Professor of Medicine, UNC School of Medicine</td>
</tr>
<tr>
<td><strong>Bert O’Neil, MD</strong>, Associate Professor of Medicine, UNC School of Medicine and Medical Director, Clinical Protocol Office, UNC Lineberger</td>
<td><strong>W. Kimryn Rathmell, MD, PhD</strong>, Associate Professor of Medicine and Genetics, UNC School of Medicine</td>
</tr>
<tr>
<td><strong>Stergios J. Moschos, MD</strong>, Clinical Associate Professor of Medicine, UNC School of Medicine</td>
<td><strong>Matthew I. Milowsky, MD</strong>, Associate Professor of Medicine and Section Chief, Genitourinary Oncology Service, UNC School of Medicine</td>
</tr>
<tr>
<td>1:15-3:20p</td>
<td>Using Molecular Markers in the Clinic</td>
</tr>
<tr>
<td><strong>Lisa A. Carey, MD</strong></td>
<td><strong>Benjamin Haithcock, MD</strong>, Associate Professor, Department of Surgery, Division of Thoracic Oncology, UNC School of Medicine</td>
</tr>
<tr>
<td><strong>Matthew A. Mauro, MD, FACS, FAHA, FSIR</strong>, Ernest H. Wood Distinguished Professor and Chair, Department of Radiology, UNC School of Medicine</td>
<td><strong>Joel Tepper, MD</strong>, Hector MacLean Distinguished Professor of Cancer Research, Department of Radiation Oncology, UNC School of Medicine</td>
</tr>
<tr>
<td>3:20-3:40p</td>
<td>Break</td>
</tr>
<tr>
<td><strong>Lisa A. Carey, MD</strong></td>
<td><strong>David Godschalk, Distinguished Professor</strong>, Department of Physics and Astronomy, and Curriculum in Applied Sciences and Engineering Lineberger Comprehensive Cancer Center</td>
</tr>
<tr>
<td><strong>Matthew A. Mauro, MD, FACS, FAHA, FSIR</strong>, Ernest H. Wood Distinguished Professor and Chair, Department of Radiology, UNC School of Medicine</td>
<td><strong>W. Kimryn Rathmell, MD, PhD</strong>, Associate Professor of Medicine and Genetics, UNC School of Medicine</td>
</tr>
<tr>
<td><strong>Stergios J. Moschos, MD</strong>, Clinical Associate Professor of Medicine, UNC School of Medicine</td>
<td><strong>David Godschalk, Distinguished Professor</strong>, Department of Physics and Astronomy, and Curriculum in Applied Sciences and Engineering Lineberger Comprehensive Cancer Center</td>
</tr>
<tr>
<td><strong>Matthew I. Milowsky, MD</strong>, Associate Professor of Medicine and Section Chief, Genitourinary Oncology Service, UNC School of Medicine</td>
<td><strong>W. Kimryn Rathmell, MD, PhD</strong>, Associate Professor of Medicine and Genetics, UNC School of Medicine</td>
</tr>
<tr>
<td><strong>Stergios J. Moschos, MD</strong>, Clinical Associate Professor of Medicine, UNC School of Medicine</td>
<td><strong>Matthew I. Milowsky, MD</strong>, Associate Professor of Medicine and Section Chief, Genitourinary Oncology Service, UNC School of Medicine</td>
</tr>
<tr>
<td><strong>W. Kimryn Rathmell, MD, PhD</strong>, Associate Professor of Medicine and Genetics, UNC School of Medicine</td>
<td><strong>Stergios J. Moschos, MD</strong>, Clinical Associate Professor of Medicine, UNC School of Medicine</td>
</tr>
<tr>
<td><strong>Matthew I. Milowsky, MD</strong>, Associate Professor of Medicine and Section Chief, Genitourinary Oncology Service, UNC School of Medicine</td>
<td><strong>W. Kimryn Rathmell, MD, PhD</strong>, Associate Professor of Medicine and Genetics, UNC School of Medicine</td>
</tr>
</tbody>
</table>
### Sunday, October 21, 2012

#### 7:30a  Registration

#### 7:50-8:00a  Welcome and Introductions

#### 8:00-9:00a  Current Issues in Cancer Screening

<table>
<thead>
<tr>
<th>Moderator</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard M. Goldberg, MD, Co-Chairman, STO; Physician-in-Chief and Professor, The Klotz Family Chair in Cancer Research, The Ohio State University Comprehensive Cancer Center and James Cancer Hospital</td>
<td></td>
</tr>
<tr>
<td>Paul Godley, MD, PhD, MPP, Professor of Medicine and Vice Dean for Faculty Affairs, UNC School of Medicine</td>
<td></td>
</tr>
<tr>
<td>Richard M. Goldberg, MD</td>
<td></td>
</tr>
<tr>
<td>Nirmal Veeramachaneni, MD, Assistant Professor, Department of Surgery, Division of Cardiothoracic Surgery, UNC School of Medicine</td>
<td></td>
</tr>
<tr>
<td>H. Shelton Earp, MD, Lineberger Professor and Director, UNC Lineberger Comprehensive Cancer Center</td>
<td></td>
</tr>
</tbody>
</table>

#### 9:00-9:40a  Special Lecture: The Impact of Genomic and Signaling Research on Clinical Research

<table>
<thead>
<tr>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>H. Shelton Earp, MD, Lineberger Professor and Director, UNC Lineberger Comprehensive Cancer Center</td>
</tr>
</tbody>
</table>

#### 9:40-10:00a  Break

#### 10:00-11:15a  Targeted Therapies for Hematologic Malignancies

<table>
<thead>
<tr>
<th>Moderator</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas C. Shea, MD, Director, UNC Bone Marrow Transplant Program and Associate Director for Outreach, UNC Lineberger Comprehensive Cancer Center</td>
<td></td>
</tr>
<tr>
<td>Kristy L. Richards, MD, PhD, Assistant Professor of Medicine, UNC School of Medicine</td>
<td></td>
</tr>
<tr>
<td>Pete Voorhees, MD, Assistant Professor of Medicine, UNC School of Medicine; Medical Director, UNC Cancer Network Clinical Trials Program</td>
<td></td>
</tr>
<tr>
<td>Stefanie Sarantopoulos, MD, PhD, Assistant Professor of Medicine, UNC School of Medicine</td>
<td></td>
</tr>
</tbody>
</table>

#### 11:15-12:15p  Implementing Commission on Cancer Survivorship Standards: The Devil is in the Details

<table>
<thead>
<tr>
<th>Moderator</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deborah K. Mayer, PhD, RN, AOCN, FAAN, Associate Professor, School of Nursing, UNC-Chapel Hill</td>
<td></td>
</tr>
<tr>
<td>Deborah K. Mayer, PhD, RN, AOCN, FAAN</td>
<td></td>
</tr>
<tr>
<td>Amy Abernethy, MD, Associate Professor of Medicine, Associate Professor of Medicine, Duke University</td>
<td></td>
</tr>
</tbody>
</table>

#### 12:15-12:30p  Summary and Future Plans

#### 12:30-1:30p  Lunch
Overview

For the third year, STO brings together a cadre of notable speakers, representing both research and clinical practice, who will convene before a fully engaged audience providing a unique opportunity for education, interaction, and collaboration.

Cancer treatment has progressed within the last decade. Researchers have a better understanding of cancer biology and viral oncology; clinical studies have identified potential cancer biomarkers, and researchers are investigating how genetic variations could be used to stratify patients for risk as well as treatment; the development of targeted therapies is advancing the practice of individualized medicine.

Ongoing professional education is an essential component of improving patient care and outcomes in the oncology setting, where advances occur rapidly. STO professional education activities help clinicians to identify best practice models, develop new clinical skills, and put current knowledge into action by:

- Bringing knowledge and strategies for critical new developments in cancer treatment into the practice environment of the community oncologist.
- Bridging the “translational gap” between discovery and delivery of care to the patient.
- Providing educational activities to improve physician competencies and strategies for screening, prevention, diagnosis, treatment, and management of patients with cancer.

Target Audience

This activity is designed to meet the educational needs of physicians, scientists, and other healthcare professionals in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer.

CME Accreditation

This activity is planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the Joint Sponsorship of the Society for Translational Oncology and the UNC Lineberger Comprehensive Cancer Center. The Society for Translational Oncology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME Designation

The Society for Translational Oncology designates this live activity for a maximum of 9 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Earn CME Credit for attending this meeting

In order to receive CME credit, learners must sign-in, review the CME information (accreditation, learning objectives, faculty disclosures, etc.), and attend the CME activity. Learners will be asked to complete an electronic activity evaluation following the meeting and indicate the number of credit hours claimed. Certificates will be provided upon successful completion of the evaluation.
Financial Disclosures

In accordance with ACCME Standards for Commercial Support and the policies of the Society for Translational Oncology (STO), persons participating in this activity who are in a position to control the content have disclosed all relevant relationships with any commercial interest. On the basis of disclosed information, STO identifies and resolves all conflicts of interest before delivery of content.

STO and UNC Lineberger Staff involved in the development of this activity have nothing to disclose.

The following faculty have indicated that they have had relevant financial relationship(s) with a commercial interest within the past 12 months or that they have nothing to disclose.

Amy P. Abernethy, MD  
To be announced

Lisa Carey, MD  
Nothing to disclose

H. Shelton Earp, MD  
To be announced

Matthew G. Ewend, MD  
Research funding: Northwest Biotherapeutics

Paul A. Godley, MD, PhD, MPP  
Nothing to disclose

Richard M. Goldberg, MD  
Consultant/advisory role: Lilly;  
Honoraria: Fresenius Kabi, Yakult;  
Research funding: Sanofi, Bayer, Myriad, Jnnerex

Benjamin Haithcock, MD  
To be announced

W. Brian Hyslop, MD, PhD  
Nothing to disclose

Hong Jin Kim, MD  
Honoraria: Speaker’s Bureau - Sanofi

Yueh “Ray” Lee, MD  
Research funding: Kodak Carestream

Matthew A. Mauro, MD, FACR, FSIR, FAHA  
Consultant/advisory role: B. Braun Medical, Inc., St. Jude’s

Deborah K. Mayer, AOCN, FAAN  
Employment: Editor, Clinical Journal of Oncology Nursing

Matthew I. Milowsky, MD  
Research funding: Dendreon, Novartis  
Stergios Moschos, MD  
Consultant/advisory role: Amgen

Hyman Muss, MD  
Consultant/advisory role: Wyeth/Pfizer, Eisai;  
Research funding: numerous trials at UNC (all support directly to UNC)

Bert H. O’Neil, MD  
To be announced

Charles M. Perou, PhD  
Employment/leadership: Bioclassifier LLC, GeneCentric Diagnostics;  
Property rights/patents: PAM50 Breast Cancer Test and Hypoxia Signature;  
Honoraria: Sanofi, Beckman Coulter;  
Ownership interest: Bioclassifier LLC, GeneCentric Diagnostics

W. Kimryn Rathmell, MD, PhD  
Research funding: GlaxoSmithKline, AVEO

Kristy L. Richards, MD, PhD  
Consultant/advisory role: Genentech

Stefanie Sarantopoulos, MD, PhD  
Nothing to disclose

Norman E. Sharpless, MD  
Employment/leadership: G1 Therapeutics;  
Intellectual property rights: G1 Therapeutics;  
Consultant/advisory role: Molecular MD, Liquidia;  
Ownership interest: G1 Therapeutics

Thomas Shea, MD  
Research funding: Millennium, GSK, BMS, Novartis, Fresenius, Otsuka

Tom Stinchcombe, MD  
Consultant/advisory role: Genentech, Lilly

Joel E. Tepper, MD  
Nothing to disclose

Nirmal Veeramachaneni, MD  
Nothing to disclose

Peter Voorhees, MD  
Consultant/advisory role: Abbott Laboratories, MedImmune, Celgene;  
Research funding: Merck, Janssen, Celgene, Pfizer, GlaxoSmithKline, Acetylon, Prolexys

Terence A. Wong, MD, PhD  
Consultant/advisory role: Lilly

Jen Jen Yeh, MD  
Nothing to disclose

Otto Zhou, PhD  
To be announced
Learning Objectives

- Describe the potential for PET as an integral imaging biomarker in therapeutic strategies.
- Discuss the utility of body MRI in certain clinical applications in oncology.
- Identify the technical advantages and limitations of PET/MR especially as related to oncological imaging.
- Describe the newer directions in catheter directed therapies and their role in the management of liver dominant metastatic disease.
- Discuss the management of patients with limited metastatic disease in multiple disciplines.
- Make better use of radiosurgery for metastases.
- Identify key prognostic factors and appropriate groups for prognostic profiling.
- Increase the application of molecular testing in non-small cell lung cancer.
- Discuss approaches to improving outcomes in pancreatic cancer.
- Describe the molecular alterations in urothelial cancer that represent potential targets for novel therapies.
- Describe the genetic programs that contribute to therapy development in kidney cancer.
- Explain prognosis behavior and proposed treatments in genetically heterogeneous melanoma subgroups.
- Perform an accurate, rapid geriatric assessment in the clinic setting.
- Describe the effectiveness of PSA screening and finasteride chemoprevention for the prevention of prostate cancer mortality and diagnosis, respectively.
- Appraise the evidence in favor of lung cancer screening.
- Describe anti-CD20 antibodies currently in development and the research needed in order to choose appropriate antibodies for patients in a given clinical scenario.
- Describe the study of patients’ samples that has led to identification of novel therapeutic targets for human chronic GVHD.
- Describe the intended purpose of survivorship care plans (SCPs).
- Identify available SCP templates.
- Analyze practice opportunities to develop and implement SCP.
2012 Bob Pinedo Cancer Care Prize Awardee

Richard L. Schilsky, MD
Professor of Medicine and Section Chief of Hematology/Oncology
The University of Chicago Department of Medicine
Chicago, Illinois

The Society for Translational Oncology is honored to award the 2012 Bob Pinedo Cancer Care Prize to Dr Richard L. Schilsky for his clinical and research leadership in the areas of gastrointestinal cancers and cancer pharmacology, coupled with his compassionate care of cancer patients. An internationally recognized expert on gastrointestinal malignancies, Dr Schilsky is also a leader in the development and evaluation of new treatments for cancer. He is past Chairman of the Cancer and Leukemia Group B, a national cancer clinical trials group sponsored by the National Cancer Institute, and former chair of the Board of Scientific Advisors of the National Cancer Institute and of the Oncology Drugs Advisory Committee of the FDA. A past president of the American Society of Clinical Oncology, Dr Schilsky was recently named an ASCO Fellow. He currently serves as an officer of the Board of Directors of the Conquer Cancer Foundation of ASCO. Among his many peer-reviewed activities, Dr. Schilsky is senior associate editor of Molecular Oncology, associate editor of the Journal of the National Cancer Institute and Seminars in Oncology, and a member of the editorial boards of The Oncologist, Clinical Cancer Research, and Cancer Prevention Research.

In honor of this award, Dr Schilsky will give the keynote lecture “Publically Funded Clinical Trials and the Future of Cancer Care” at the STO Third Annual Meeting, hosted by UNC Lineberger Comprehensive Cancer Center at the Rizzo Center in Chapel Hill, NC, October 20-21, 2012.

About the Prize
The prize honors Professor H.M. (Bob) Pinedo, founder of the VU University Medical Center (VUmc) Cancer Center Amsterdam (CCA), who weds world-class cancer research with a devotion to his patients and their families. In the past six years, the Bob Pinedo Cancer Care Prize has been awarded to:

- Bruce Chabner, MD – Massachusetts General Hospital Cancer Center
- Joseph Bertino, MD – The Cancer Institute of New Jersey
- Bob Löwenberg, MD – Erasmus University Medical Centre
- Richard O’Reilly, MD – Memorial Sloan-Kettering Cancer Center
- José Baselga, MD, PhD – Massachusetts General Hospital Cancer Center
- Gabriel N. Hortobágyi, MD – The University of Texas MD Anderson Cancer Center

Call for Nominations
Nominations for the 2013 Pinedo Prize will be received by Professor Patrick Johnston, Chairman, Nominating Committee: Pinedo.Prize@STO-online.org until February 1, 2013. All nominees will be evaluated by an international jury.

Direct questions about STO or the Bob Pinedo Cancer Care Prize to: admin@sto-online.org.
STO gratefully acknowledges educational grants in partial support of this meeting from the North Carolina Biotechnology Center, Pfizer, and Quintiles.